As previously reported, Craig-Hallum analyst Adam Vogel initiated coverage of Design Therapeutics (DSGN) with a Buy rating and $15 price target The firm sees an attractive catalyst path into second half of 2026, where two independent clinical readouts will test the GeneTAC gene modulatory platform. With an enterprise value of about $300M and limited platform credit in the stock today, Craig-Hallum views Design Therapeutics as an asymmetric genetic-medicine opportunity where success in either Friedreich’s Ataxia or Fuchs could drive meaningful re-rating.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Design Therapeutics initiated with a Buy at Craig-Hallum
- Design Therapeutics upgraded to Outperform from Market Perform at Leerink
- RBC upgrades Design Therapeutics to Outperform into ‘more eventful’ 2026
- Design Therapeutics upgraded to Outperform from Sector Perform at RBC Capital
- Design Therapeutics Reports Q3 2025 Financial Results